Silencing of Fanconi anemia complementation group F exhibits potent Chemosensitization of mitomycin C activity in breast cancer cells

Journal of Breast Cancer

Volumn 16, Issue 3, 2013, Pages 291-299

  Yu, Jiankun ^a   Zhao, Lin ^a   Li, Yanlin ^a   Li, Na ^a   He, Miao ^a   Bai, Xuefeng ^a   Yu, Zhaojin ^a   Zheng, Zhihong ^b   Mi, Xiaoyi ^b   Wang, Enhua ^b   Wei, Minjie ^a,b  

^a Department of Pharmacology and 2Institute of Pathology and Pathophysiology ^*  (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast neoplasms; Fanconi anemia complementation group F protein; Mitomycin C; Tumor cell line

Indexed keywords

FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP F PROTEIN; MITOMYCIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA FRAGMENTATION; DRUG ACCUMULATION; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; UBIQUITINATION; WESTERN BLOTTING;

EID: 84885741909     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2013.16.3.291     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Aldabbagh K, Pouderoux S, Roca L, Poujol S, Fabbro M, Romieu G, et al. Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study. Breast Cancer 2012;19:16-22.
3. Urruticoechea A, Archer CD, Assersohn LA, Gregory RK, Verrill M, Mendes R, et al. Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. Br J Cancer 2005;92:475-9.
4. Celli CM, Jaiswal AK. Role of GRP58 in mitomycin C-induced DNA cross-linking. Cancer Res 2003;63:6016-25.
5. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001;2:483-90.
6. Bagby GC, Alter BP. Fanconi anemia. Semin Hematol 2006;43:147-56.
7. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res 2009;668: 4-10.
8. Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011;43: 138-41.
9. Bogliolo M, Lyakhovich A, Callén E, Castellà M, Cappelli E, Ramírez MJ, et al. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J 2007;26: 1340-51.
10. Lyakhovich A, Surrallés J. New roads to FA/BRCA pathway: H2AX. Cell Cycle 2007;6:1019-23.
11. Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003;3:417-20.
12. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005;106:698-705.
13. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 2004;64: 2994-7.
14. Chen CC, Taniguchi T, D'Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med (Berl) 2007;85:497-509.
15. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-91.
16. Léveillé F, Blom E, Medhurst AL, Bier P, Laghmani el H, Johnson M, et al. The Fanconi anemia gene product FANCF is a flexible adaptor protein. J Biol Chem 2004;279:39421-30.
17. Kowal P, Gurtan AM, Stuckert P, DAndrea AD, Ellenberger T. Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex. J Biol Chem 2007;282:2047-55.
18. Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW, et al. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 1992;31:7879-85.
19. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010;29:405-34.
20. Tamm I, Schriever F, Dörken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol 2001;2:33-42.
21. DAndrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003;2:290-2.
22. Burkitt K, Ljungman M. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol Cancer 2008;7:24.
23. Hortobagyi GN. Mitomycin-C in breast cancer. Semin Oncol 1985;12: 65-70.
24. Godfrey TE. Mitomycin C in advanced breast cancer: an update. Semin Oncol 1988;15:71-3.
25. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
26. Jiang YY, Wang HJ, Wang J, Tashiro S, Onodera S, Ikejima T. The protective effect of silibinin against mitomycin C-induced intrinsic apoptosis in human melanoma A375-S2 cells. J Pharmacol Sci 2009;111:137-46.
27. Moldovan GL, DAndrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009;43:223-49.
28. Barroso E, Pita G, Arias JI, Menendez P, Zamora P, Blanco M, et al. The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features. Breast Cancer Res Treat 2009; 118:655-60.